Bellicum Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders.
BLCM has three product candidates in clinical development: BPX-501, an adjunct T-cell therapy product candidate being evaluated in Phase I/II clinical trials in children and adults following a T-depleted, haploidentical hematopoietic stem cell transplant (HSCT); BPX-601, a GoCAR-T product candidate in Phase I development for solid tumors expressing the prostate stem cell antigen; and BPX-701, a T cell receptors (TCR) product candidate in Phase I development for AML with future development potential for treatment of solid tumors expressing the preferentially-expressed antigen in melanoma.
BLCM has collaboration agreements with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T-cell therapies; Ospedale Pediatrico Bambino Gesú for the design and development of various T cell immunotherapies; and Academisch Ziekenhuis Leiden for research to discover and validate high-affinity TCR product candidates targeting various cancer-associated antigens.
Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.
April 23, 2024
RegMed Investors (RMi) Closing Bell: welcoming the upside trend
April 22, 2024
RegMed Investors (RMi) Closing Bell: a flash sector relief rally?
April 5, 2024
RegMed Investors (RMi) Closing Bell: economic circumstances drove a 5 session/weekly downside
April 4, 2024
RegMed Investors (RMi) Closing Bell: economics undermine sector’s share pricing before jobs report
April 3, 2024
RegMed Investors (RMi) Closing Bell: The switch is still flipped
April 2, 2024
RegMed Investors (RMi) Closing Bell: weakness is more of a wipe-out
April 2, 2024
RegMed Investors (RMi) - Q4/23 & FY23 Cell and Gene Therapy Earnings Scorecard Results
April 1, 2024
RegMed Investors (RMi) Closing Bell: An early share pricing eclipse in first session of April?
March 29, 2024
RegMed Investors (RMi) Closing Bell: done and over, portfolios escaped bloodied but, relatedly intact
35 companies, 1 interpreter!
Insight, foresight and recommendation
Bellicum Pharmaceuticals (BCLM) - January '18 opened at $9.23, slipping to a low of $6.80 on 1/31 flowed by 2/1's $5.87 yet jumping to $6.60 by 2/16. After the KITE and JUNO acquisitions, many percieve that BLCM could be percieved as an appreciator in 2018 ... We do NEED to remember; the U.S. FDA placed a clinical hold on its lead product candidate BPX-501 that's being assessed as an adjunct T-cell therapy administered after haploidentical hematopoietic stem cell transplant. The hold reportedly stems from three cases of potentially treatment-related encephalopathy (abnormal brain function) that occurred during an ongoing trial. BLCM's shares were down 1/31/18 by 33.5% on heavy volume in response to this news.
buyMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors